Next Article in Journal
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults
Previous Article in Journal
Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials
 
 
Article

Article Versions Notes

Vaccines 2021, 9(12), 1467; https://doi.org/10.3390/vaccines9121467
Action Date Notes Link
article xml file uploaded 11 December 2021 10:32 CET Original file -
article xml uploaded. 11 December 2021 10:32 CET Update https://www.mdpi.com/2076-393X/9/12/1467/xml
article pdf uploaded. 11 December 2021 10:32 CET Version of Record https://www.mdpi.com/2076-393X/9/12/1467/pdf
article supplementary file uploaded. 11 December 2021 10:32 CET - https://www.mdpi.com/2076-393X/9/12/1467#supplementary
article html file updated 11 December 2021 10:33 CET Original file -
article html file updated 30 July 2022 21:45 CEST Update https://www.mdpi.com/2076-393X/9/12/1467/html
Back to TopTop